new-recommended-broker-banner new-recommended-broker-banner

Mesoblast Stock Up 77% On Clinical Trial Results

Updated: 11 Jan 2021

Mesoblast (NASDAQ: MESO) shares are climbing premarket on Monday after the company released clinical trial results for its drug rexlemestrocel-L, showing promising signs.

Mesoblast’s US-listed shares are up 77.48% at $15.37 after its Australian-listed shares closed 14.29%.

The results from the DREAM-HF randomised controlled Phase 3 trial showed that a single dose of rexlemestrocel-L resulted in substantial and durable reductions in heart attacks, strokes, and cardiac deaths. The trial enrolled 537 treated patients with chronic heart failure and reduced left ventricular ejection fraction.

new-recommended-broker-banner

Since existing therapies have minimal or no benefit on these endpoints, Mesoblast feels the outcomes may signal a breakthrough in addressing the unmet needs in patients with chronic heart failure.

Heart attacks and strokes were reduced by 60% over an average follow-up period of 30 months following a single dose of rexlemestrocel-L in the group of 537 patients with New York Heart Association class II or III chronic heart failure.

Rexlemestrocel-L significantly reduced Major Adverse Cardiovascular Events (MACE) by 30% compared to controls across the population of 537 patients.

Mesoblast said it now intends to meet with the US Food and Drug Administration (FDA) to discuss a potential pathway to approval.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .